Drug Trial Radar · NCT07707375
A Study of LY4268989 (MORF 057) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 20, 2026
Primary completion
Oct 8, 2026
Study completion Oct 8, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to identify if two different tablets of LY4268989 (MORF 057) work similarly in healthy participants given different meals. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. There will be 18 inpatient stays at the clinical research unit (CRU). The study will last about 9 weeks.
Conditions
- Healthy
Interventions
LY4268989Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989Time frame: Day 1 to Day 18
- PK: Area Under the Concentration Curve (AUC) of LY4268989Time frame: Day 1 to Day 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Daytona Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.